8-K: Current report
Published on
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class | Trading Symbols | Name of each exchange on which registered | ||
(Nasdaq Capital Market) | ||||
(Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
At the Special Meeting of Stockholders of bioAffinity Technologies, Inc. (the “Company”) held on November 20, 2026 (the “Special Meeting”), stockholders approved an amendment to the Company’s Certificate of Incorporation to decrease the total number of authorized shares of common stock, par value $0.007 per share (the “Common Stock”), from 350,000,000 shares to 200,000,000 shares (the “Charter Amendment”). On November 20, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware, and the Charter Amendment became effective immediately upon filing.
The foregoing description of the Charter Amendment is qualified in its entirety by reference to the text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K.
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the Special Meeting, the Company’s stockholders voted on five proposals, each of which is listed below and described in more detail in the Company’s Definitive Proxy Statement dated October 23, 2026 (the “Proxy Statement”). With respect to each proposal, holders of the Company’s Common Stock were entitled to cast one vote per share of Common Stock held as of the close of business on the record date of September 23, 2026 (the “Record Date”). On the Record Date, there were 1,166,625 shares of the Company’s Common Stock outstanding and entitled to vote at the Special Meeting.
The following are the final results of voting on each of the proposals presented at the Special Meeting:
Proposal No. 1: August Warrant Exercise Proposal
The stockholders approved the issuance, pursuant to Nasdaq listing rules, of up to an aggregate of 1,128,272 shares of Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with the private placement offering that closed on August 14, 2026.
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||
| 61,862 | 35,286 | 834 | 427,784 | |||||
Proposal No. 2: October Warrant Exercise Proposal
The stockholders approved the issuance, pursuant to Nasdaq listing rules, of up to an aggregate of 980,072 shares of Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with the private placement offering that closed on October 8, 2026.
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||
| 61,180 | 33,081 | 3,721 | 427,784 | |||||
Proposal No. 3: Offering Proposal
The stockholders approved the issuance of securities in one or more non-public offerings in accordance with Nasdaq Marketplace Rule 5635(d).
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||
| 50,700 | 28,910 | 18,372 | 427,784 | |||||
Proposal No. 4: Decrease in Authorized Shares Proposal
The stockholders approved an amendment to the Company’s Certificate of Incorporation to decrease the total number of authorized shares of Common Stock from 350,000,000 shares to 200,000,000 shares.
| Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||||
| 319,130 | 149,445 | 57,191 | - | ||||||
Proposal No. 5: Adjournment Proposal
The stockholders approved the adjournment of the Special Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event of insufficient votes for, or otherwise in connection with, approval of Proposal Nos. 1, 2, 3 and/or 4. However, such an adjournment was not necessary in light of the approval of Proposal Nos. 1, 2, 3 and 4 at the Special Meeting.
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 308,230 | 159,496 | 58,040 | - | |||||||||||
Item 9.01. Financial Statements and Exhibits.
| (d) | Exhibits. |
| Exhibit Number | Description | |
| 3.1 | Certificate of Amendment to the Certificate of Incorporation of bioAffinity Technologies, Inc., dated November 20, 2026. | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 20, 2026 | BIOAFFINITY TECHNOLOGIES, INC. | |
| By: | /s/ Maria Zannes | |
| Name: | Maria Zannes | |
| Title: | President and Chief Executive Officer | |